Telesis Bio (TBIO) Competitors $0.40 -0.02 (-5.71%) As of 12:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends TBIO vs. SPEC, SMIT, THMO, HTGMQ, OLITW, PRENW, QSIAW, SMAPW, TT, and KEYSShould you be buying Telesis Bio stock or one of its competitors? The main competitors of Telesis Bio include Spectaire (SPEC), Schmitt Industries (SMIT), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), and Keysight Technologies (KEYS). These companies are all part of the "measuring and control equipment" industry. Telesis Bio vs. Spectaire Schmitt Industries ThermoGenesis HTG Molecular Diagnostics OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Keysight Technologies Spectaire (NASDAQ:SPEC) and Telesis Bio (NASDAQ:TBIO) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of SPEC or TBIO? 26.6% of Spectaire shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 25.4% of Spectaire shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor SPEC or TBIO? Telesis Bio received 9 more outperform votes than Spectaire when rated by MarketBeat users. Likewise, 52.94% of users gave Telesis Bio an outperform vote while only 0.00% of users gave Spectaire an outperform vote. CompanyUnderperformOutperformSpectaireOutperform VotesNo VotesUnderperform Votes1100.00% Telesis BioOutperform Votes952.94% Underperform Votes847.06% Does the media favor SPEC or TBIO? In the previous week, Spectaire's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score. Company Overall Sentiment Spectaire Neutral Telesis Bio Neutral Which has more risk and volatility, SPEC or TBIO? Spectaire has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Is SPEC or TBIO more profitable? Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.Company Net Margins Return on Equity Return on Assets SpectaireN/A -81.22% 304.57% Telesis Bio -336.59%N/A -61.89% Which has higher valuation & earnings, SPEC or TBIO? Spectaire has higher earnings, but lower revenue than Telesis Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpectaireN/AN/A$8.95MN/AN/ATelesis Bio$225.09M0.00-$47.72M-$28.20-0.01 SummaryTelesis Bio beats Spectaire on 6 of the 10 factors compared between the two stocks. Get Telesis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart TBIO vs. The Competition Export to ExcelMetricTelesis BioAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$746,000.00$5.90B$5.39B$9.13BDividend YieldN/A0.42%5.37%4.00%P/E Ratio-0.0130.7288.8317.53Price / Sales0.004.231,282.2680.28Price / CashN/A40.3036.6032.90Price / Book2.832.464.964.69Net Income-$47.72M$2.94M$117.89M$224.57M7 Day Performance-3.72%2.92%2.75%3.33%1 Month Performance-15.74%4.04%3.63%5.33%1 Year Performance-93.07%-18.40%27.27%22.97% Telesis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBIOTelesis BioN/A$0.40-5.7%N/A-92.6%$746,000.00$225.09M-0.01200SPECSpectaireN/A$0.02+11.7%N/A-99.9%$457,000.00N/A0.008Gap UpSMITSchmitt IndustriesN/A$0.02+19.9%N/AN/A$82,000.00$9.89M0.00160Gap UpTHMOThermoGenesisN/A$0.00flatN/A-99.8%$6,000.00$9.61M0.0040High Trading VolumeHTGMQHTG Molecular DiagnosticsN/AN/AN/AN/A$0.00$6.37M0.0090OLITWOmniLit AcquisitionN/A$0.12-0.7%N/A-5.8%$0.00N/A0.003Gap DownPRENWPrenetics GlobalN/A$0.01+7.4%N/AN/A$0.00$25.56M0.001Positive NewsQSIAWQuantum-SiN/A$0.59-34.1%N/A+484.6%$0.00$2.27M0.00159Positive NewsGap DownSMAPWSportsMap Tech AcquisitionN/A$0.07+36.6%N/AN/A$0.00N/A0.00N/AHigh Trading VolumeTTTrane Technologies4.2868 of 5 stars$376.88-0.1%$414.43+10.0%+56.5%$84.81B$19.39B34.9640,000Positive NewsKEYSKeysight Technologies4.6925 of 5 stars$161.16-0.1%$180.80+12.2%+7.9%$27.91B$4.98B46.0514,900Positive News Related Companies and Tools Related Companies Spectaire Competitors Schmitt Industries Competitors ThermoGenesis Competitors HTG Molecular Diagnostics Competitors OmniLit Acquisition Competitors Prenetics Global Competitors Quantum-Si Competitors SportsMap Tech Acquisition Competitors Trane Technologies Competitors Keysight Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TBIO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
